Pfizer’s board of directors will meet on November 12, 2025, to review and approve the unaudited financial results for the second quarter (Q2: Jul-Sep) and half-year ended September 30, 2025. The results will be publicly available 48 hours after the board meeting.
Board Meeting Announcement
The Board of Directors of Pfizer is scheduled to convene on November 12, 2025, to consider and approve the unaudited financial results. This meeting is an important step in the company’s financial reporting process.
Financial Results Under Review
The primary agenda of the meeting is to review the company’s financial performance for both the quarter and half-year periods ending September 30, 2025. These results provide a snapshot of the company’s financial health and operational effectiveness during these periods.
Trading Window Closure
As per company policy, the trading window for dealing in the company’s shares was closed starting September 30, 2025. This closure will extend until 48 hours after the unaudited financial results are officially released to the public on November 12, 2025. This measure ensures compliance with insider trading regulations.
Source: BSE
